Used in targeted cancer therapy, particularly in inhibiting tumor angiogenesis and growth in solid tumors expressing EFNA4. This monoclonal antibody blocks the interaction between EFNA4 and its receptor, disrupting signaling pathways involved in tumor cell survival and blood vessel formation. It has been investigated in clinical trials for cancers such as non-small cell lung cancer and ovarian cancer, aiming to suppress metastasis and improve patient outcomes. Its high specificity allows for precise targeting, reducing off-target effects commonly seen in conventional chemotherapy.